The European Medicines Agency (EMA) has approved Janssen‘s continuous manufacturing (CM) with real-time release testing for the production of Prezista (darunavir) 600 mg tablets.
In 2016, Janssen became the first in the industry to receive FDA approval to convert from batch to CM. With this EMA approval, Janssen is able to reduce manufacturing and testing cycle time, reduce waste and environmental impact, and lower process risk, all while maintaining existing product quality in the delivery of innovative therapies for patients.
Here a infographic, created by Janssen, to show the value of CM in the pharmaceutical industry
click here to download the file : Janssen-Infographic
